Cadrenal Therapeutics (Nasdaq: CVKD), a US-based biopharmaceutical company, announced on Monday that it has received a Fast Track designation from the US Food and Drug Administration (FDA) for its tecarfarin, intended to prevent systemic thromboembolism, more commonly referred to as blood clots, of cardiac origin in patients with end-stage renal disease (ESRD) and atrial fibrillation (AFib).

Quang Pham, Cadrenal chief executive officer, said, 'The Fast Track designation for tecarfarin is an important milestone in the development of this therapy and highlights the importance of finding an effective treatment for the prevention of blood clots of cardiac origin in patients with ESRD and AFib. We look forward to working closely with the FDA to evaluate this therapy as a potential new treatment option for this underserved patient population.'

The FDA had earlier granted tecarfarin Orphan Drug Designation (ODD).